Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=41233468
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Treatment of initially unresectable local advanced pancreatic adenocarcinoma with
FOLFIRINOX: A prospective study YCOG1403 (C-FLAP study)
#MMPMID41233468
Kobayashi N
; Yabushita Y
; Mori R
; Takahashi T
; Miyake K
; Sawada Y
; Homma Y
; Matsuyama R
; Okubo N
; Katsuta E
; Kubota K
; Yamanaka S
; Ichikawa Y
; Endo I
Sci Rep
2025[Nov]; 15
(1
): 39884
PMID41233468
show ga
This study aimed to provide evidence regarding the treatment of patients with
unresectable pancreatic cancer. We conducted a prospective single-arm phase II
trial using the FOLFIRINOX regimen. After completing 4-8 cycles, patients
underwent surgical resection when feasible. The primary endpoint was R0 resection
rate. Fifteen patients were enrolled in this study. A median of six courses of
FOLFIRINOX chemotherapy was administered, and a partial response or R0 resection
was achieved in 26.7% and 33% of the patients, respectively. Severe adverse
events due to chemotherapy and major surgical complications were observed in
33.3% and 6.7% of patients, respectively. The median overall survival of patients
who underwent R0 resection or with R1 or unresectable disease was 47.8 months
(95% confidence interval (CI), 22.5-73.1) or 14.5 months (95% CI, 11.8-17.2),
respectively (P?=?0.031). Well-selected patients with unresectable locally
advanced pancreatic cancer treated with FOLFIRINOX achieved relatively high R0
resection rates and prolonged survival. Therefore, induction with FOLFIRINOX is
feasible and well tolerated for locally advanced, initially unresectable
pancreatic cancer and may be effective in facilitating R0 resection and
prolonging survival.
free
free
free
